Sorrento Therapeutics, Inc.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 2006-01-01
- Employees
- 949
- Market Cap
- -
Clinical Trials
46
Active:3
Completed:10
Trial Phases
4 Phases
Phase 1:21
Phase 2:20
Phase 3:3
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (45 trials with phase data)β’ Click on a phase to view related trials
Phase 1
21 (46.7%)Phase 2
20 (44.4%)Phase 3
3 (6.7%)Not Applicable
1 (2.2%)An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL Amyloidosis
Phase 1
Withdrawn
- Conditions
- Light Chain (AL) Amyloidosis
- First Posted Date
- 2023-01-20
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Registration Number
- NCT05692908
Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Advanced Solid Tumor
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT05584709
- Locations
- πΊπΈ
Columbia University Medical Center, New York, New York, United States
Long-Term Follow-Up of Patients Who Received Gene-Modified Cell Therapy
- Conditions
- Long-term Follow-up
- First Posted Date
- 2022-07-25
- Last Posted Date
- 2023-01-23
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT05472649
- Locations
- πΊπΈ
Abramson Cancer Center Clinical Research Unit, University of Pennsylvania, Philadelphia, Pennsylvania, United States
Study to Evaluate the Efficacy of IN STI-9199 in Treating Symptomatic COVID-19 in Outpatient Adults and Adolescents
- First Posted Date
- 2022-05-13
- Last Posted Date
- 2023-02-13
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Registration Number
- NCT05372783
- Locations
- πΊπΈ
ProSciento, Inc., Chula Vista, California, United States
Study to Assess the Safety, Tolerability and Pharmacokinetics of STI-1558 in Healthy Volunteers
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT05364840
- Locations
- π¦πΊ
Scientia Clinical Research Ltd, Randwick, New South Wales, Australia
- Prev
- 1
- 2
- 3
- 4
- 5
- 10
- Next
News
No news found